Search

Your search keyword '"Crowson, Cynthia s."' showing total 1,177 results
Start Over Author "Crowson, Cynthia s." Language english
1,177 results on '"Crowson, Cynthia s."'

5. Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort

Author

Karmacharya, Paras, Crowson, Cynthia S., Lennon, Ryan J., Poudel, Dilli, Davis, John M, III, Ogdie, Alexis, Liew, Jean W., Ward, Michael M., Ishimori, Mariko, Weisman, Michael H., Brown, Matthew A., Rahbar, Mohammad H., Hwang, Mark C., Reveille, John D., and Gensler, Lianne S.

Published
2024
Full Text
View/download PDF

6. Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity

Author

Cunningham, Kevin Y., Hur, Benjamin, Gupta, Vinod K., Arment, Courtney A., Wright, Kerry A., Mason, Thomas G., Peterson, Lynne S., Bekele, Delamo I., Schaffer, Daniel E., Bailey, Marissa L., Delger, Kara E., Crowson, Cynthia S., Myasoedova, Elena, Zeng, Hu, Rodriguez, Moses, Weyand, Cornelia M., Davis, III, John M., and Sung, Jaeyun

Published
2023
Full Text
View/download PDF

9. Clinical features, risk factors, and outcomes of diffuse alveolar hemorrhage in antiphospholipid syndrome: A mixed-method approach combining a multicenter cohort with a systematic literature review

Author

Figueroa-Parra, Gabriel, Meade-Aguilar, Jose A., Langenfeld, Hannah E., González-Treviño, Mariana, Hocaoglu, Mehmet, Hanson, Andrew C., Prokop, Larry J., Murad, M. Hassan, Cartin-Ceba, Rodrigo, Specks, Ulrich, Majithia, Vikas, Crowson, Cynthia S., and Duarte-García, Alí

Published
2023
Full Text
View/download PDF

12. Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case–control study

Author

Kronzer, Vanessa L, Hayashi, Keigo, Yoshida, Kazuki, Davis, John M, III, McDermott, Gregory C, Huang, Weixing, Dellaripa, Paul F, Cui, Jing, Feathers, Vivi, Gill, Ritu R, Hatabu, Hiroto, Nishino, Mizuki, Blaustein, Rachel, Crowson, Cynthia S, Robinson, William H, Sokolove, Jeremy, Liao, Katherine P, Weinblatt, Michael E, Shadick, Nancy A, Doyle, Tracy J, and Sparks, Jeffrey A

Published
2023
Full Text
View/download PDF

17. Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit

Author

Athanasios Karpouzas, George, Gonzalez-Gay, Miguel A, Sfikakis, Petros P, Tektonidou, Maria G, Lazarini, Argyro, Vassilopoulos, Dimitrios, Kuriya, Bindee, Hitchon, Carol, Simona Stoenoiu, Maria, Durez, Patrick, Pascual-Ramos, Virginia, Angel Galarza-Delgado, Dionicio, Faggiano, Pompilio, Prasanna Misra, Durga, Borg, Andrew A, Mu, Rong, Mirrakhimov, Erkin M, Gheta, Diane, Douglas, Karen, Agarwal, Vikas, Myasoedova, Svetlana, Krougly, Lev, Valentinovna Popkova, Tatiana, Tuchyňová, Alena, Tomcik, Michal, Vrablik, Michal, Lastuvka, Jiri, Horak, Pavel, Kaspar Medkova, Helena, Semb, Anne Grete, Rollefstad, Silvia, Sexton, Joseph, Ikdahl, Eirik, Crowson, Cynthia S., van Riel, Piet, Kitas, George, Graham, Ian, and Kerola, Anne M.

Published
2022
Full Text
View/download PDF

19. Subclinical aortic inflammation in patients with polymyalgia rheumatica.

Author

Kaymakci, Mahmut S, Berry, Gerald J, Langenfeld, Hannah E, Hanson, Andrew C, Crowson, Cynthia S, Bois, Melanie C, Schaff, Hartzell V, Sato, Yuki, Le, Kevin-Phu C, Koster, Matthew J, Weyand, Cornelia M, and Warrington, Kenneth J

Subjects
MORTALITY risk factors, AORTIC aneurysms, RESEARCH funding, POLYMYALGIA rheumatica, GIANT cell arteritis, DESCRIPTIVE statistics, AORTA, LONGITUDINAL method, MEDICAL records, ACQUISITION of data, INFLAMMATION, COMPARATIVE studies, CONFIDENCE intervals, THORACIC aorta, NOSOLOGY
Abstract

Objectives To examine the clinicopathologic features of patients with polymyalgia rheumatica (PMR) who had thoracic aorta repair surgery. Findings were compared with those of a cohort of patients with giant cell arteritis (GCA) requiring thoracic aorta repair. Methods All patients evaluated at Mayo Clinic in Rochester, MN, with Current Procedural Terminology (CPT) codes for thoracic aorta repair surgery between 2000–2021 were identified. All patients were screened for prior PMR diagnosis. Patients with PMR and no signs of GCA were categorized as clinically isolated PMR. The medical records of all patients were manually reviewed, and pathologists re-examined all the aortic tissues. Results Of the 4621 patients with at least one CPT code for thoracic aorta repair surgery, 43 patients were diagnosed with clinically isolated PMR before the surgery. Detailed histopathological examination of the aortic tissues revealed active inflammation in 30/43 (70%) patients after a median (IQR) of 10.0 (4.7–13.3) years from the PMR diagnosis. When compared with aortic tissue from patients with a prior diagnosis of GCA, the aorta of patients with PMR had more severe inflammation (Grade 3: 15/30 [50%] vs 5/34 [15%], P  = 0.002). Patients with PMR and thoracic aorta repair may experience a 40% increased risk of mortality compared with the general population, but this did not reach statistical significance (standardized mortality ratio: 1.40; 95% CI: 0.91–2.07). Conclusions Some patients with PMR have subclinical aortic inflammation that is detectable many years after initial diagnosis and may contribute to the development of aortic aneurysm. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network.

Author

Figueroa-Parra, Gabriel, Meade-Aguilar, Jose A, Hulshizer, Cassondra A, Gunderson, Tina M, Chamberlain, Alanna M, Thanarajasingam, Uma, Greenlund, Kurt J, Barbour, Kamil E, Crowson, Cynthia S, and Duarte-García, Alí

Subjects
RISK assessment, RESEARCH funding, LOGISTIC regression analysis, SYSTEMIC lupus erythematosus, SEVERITY of illness index, DESCRIPTIVE statistics, CHI-squared test, MANN Whitney U Test, ODDS ratio, LONGITUDINAL method, DATA analysis software, CONFIDENCE intervals, COMORBIDITY, PROPORTIONAL hazards models
Abstract

Objectives The objectives of this study were to assess the prevalence and incidence of multimorbidity and its association with the SLICC/ACR damage index (SDI) among patients with SLE. Methods Using prevalent and incident population–based cohorts of patients with SLE and their matched comparators, we assessed 57 chronic conditions. Chronic conditions were categorized as SDI-related or SDI-unrelated. Multimorbidity was defined as the presence of two or more chronic conditions. The prevalence of multimorbidity for both cohorts was compared using logistic regression. Cox models were used to examine the development of multimorbidity after SLE incidence. Results The prevalent cohort included 449 patients with established SLE on 1 January 2015. They were three times more likely to have multimorbidity compared with non-SLE comparators [odds ratio (OR) 2.98, 95% CI 2.18–4.11]. The incident cohort included 270 patients with new-onset SLE. At SLE incidence, patients with SLE were more likely to have multimorbidity than comparators (OR 2.27, 95% CI 1.59–3.27). After incidence, the risk of developing multimorbidity was 2-fold higher among patients with SLE than among comparators [hazard ratio (HR) 2.11, 95% CI 1.59–2.80]. The development of multimorbidity was higher in patients with SLE based on SDI-related conditions (HR 2.91, 95% CI 2.17–3.88) than on SDI-unrelated conditions (HR 1.73, 95% CI, 1.32–2.26). Conclusion Patients with SLE had a higher burden of multimorbidity, even before the onset of the disease. The risk disparity continued after SLE classification and was also seen in a prevalent SLE cohort. Multimorbidity was driven both by SDI-related and unrelated conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Clinical phenotype, NOD2 genotypes, and treatment observations in Yao syndrome: a retrospective case series.

Author

Williamson, Katrina A., Samec, Matthew J., Patel, Jenny A., Orandi, Amir B., Wang, Benjamin, Crowson, Cynthia S., Loftus Jr., Edward V., Alavi, Afsaneh, Moyer, Ann M., and Davis III, John M.

Subjects
DYSAUTONOMIA, MAST cells, SYMPTOMS, MEDICAL records, AGE of onset
Abstract

Objective: The aim of this study was to characterize the phenotype and genotype of patients with Yao syndrome (YAOS), with focus on comparing to prior cohorts, identifying novel features, and describing treatment observations. Methods: A retrospective medical records review of patients with YAOS seen at Mayo Clinic was conducted to characterize clinical features, NOD2 genotypes, and therapeutic trials and responses. Results: Twenty-two patients diagnosed with YAOS were included. Eighteen patients (81.8%) were female and twenty (90.9%) were White. Mean age at symptom onset was 24.0 ± 14.8 years. Common clinical manifestations included fever (81.8% of patients), rash (95.5%), chronic gastrointestinal symptoms (100%), arthralgia/arthritis (95.5%), and sicca symptoms (68.2%). NOD2 genotypes as single variants included IVS8 + 158 in 14 patients (63.6%), R702W in 8 patients (36.4%), 1007fs in 4 (18.2%), and one patient had only a previously unreported rare variant. Eight patients (36.4%) had compound (two or more) NOD2 variants. Potential comorbidities of YAOS observed in this cohort included gastrointestinal dysmotility, autonomic dysfunction, and mast cell activation-like symptoms. Glucocorticoid responsiveness was observed in 15 of 20 patients exposed (75%). Eleven patients (50.0%) received IL-1 inhibitor therapy, and one patient (4.5%) received IL-6 inhibitor therapy with adequate disease control. Conclusion: Our findings substantiate the occurrence of fevers, arthralgia/ arthritis, rash, chronic gastrointestinal symptoms, and sicca-like symptoms described previously in patients with YAOS. Novel clinical features and one NOD2 variant not previously described were identified. Glucocorticoids, biologic IL-1 inhibitors, and IL-6 receptor inhibitors appeared to be effective for treatment of patients with YAOS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta‐Analysis of the Control Arms of Randomized Controlled Trials.

Author

Figueroa‐Parra, Gabriel, Cuéllar‐Gutiérrez, María C., González‐Treviño, Mariana, Sanchez‐Rodriguez, Alain, Flores‐Gouyonnet, Jaime, Meade‐Aguilar, José A., Prokop, Larry J., Murad, M. Hassan, Dall'Era, María, Rovin, Brad H., Houssiau, Frédéric, Tamirou, Farah, Fervenza, Fernando C., Crowson, Cynthia S., Putman, Michael S., and Duarte‐García, Alí

Subjects
MORTALITY, BIOPSY, COMBINATION drug therapy, PROTEINURIA, LUPUS nephritis, IMMUNOSUPPRESSIVE agents, DEATH, RESEARCH funding, PATHOLOGIC complete response, MYCOPHENOLIC acid, DRUG therapy, INFECTION, TREATMENT effectiveness, META-analysis, PREDNISONE, DESCRIPTIVE statistics, SYSTEMATIC reviews, DOSE-effect relationship in pharmacology, CONFIDENCE intervals, GLUCOCORTICOIDS, KIDNEYS, CYCLOPHOSPHAMIDE, THERAPEUTICS
Abstract

Objective: Our objective was to evaluate the effect of glucocorticoid regimens on renal response, infections, and mortality among patients with lupus nephritis (LN). Methods: We performed a systematic review and meta‐analysis of the control arms of randomized clinical trials (RCTs). We included RCTs of biopsy‐proven LN that used a protocolized regimen of glucocorticoids in combination with mycophenolic acid analogs or cyclophosphamide and reported the outcomes of complete response (CR), serious infections, and death. The starting dosage of glucocorticoids, tapering method, and administration of glucocorticoid pulses were abstracted. Meta‐analysis of proportions, meta‐regression, and subgroup meta‐analysis were performed at 6 and 12 months for all outcomes. Results: Fifty RCT arms (3,231 patients with LN) were included. The predicted rates of CR, serious infections, and death when starting on oral prednisone at 25 mg/day without pulses were 19.5% (95% confidence interval [CI] 7.3–31.5), 3.2% (95% CI 2.4–4.0), and 0.2% (95% CI 0.0–0.4), respectively. Starting on prednisone at 60 mg/day (without pulses) increased the rates to 34.6% (95% CI 16.9–52.3), 12.1% (95% CI 9.3–14.9), and 2.7% (95% CI 0.0–5.3), respectively. Adding glucocorticoid pulses increased the rates of CR and death but not serious infections. We observed a dose–response gradient between the initial glucocorticoid dosage and all the outcomes at six months after accounting for the administration of glucocorticoid pulses, underlying immunosuppressant, and baseline proteinuria. Conclusion: A higher exposure to glucocorticoids during the initial therapy of LN was associated with better renal outcomes at the cost of increased infections and death. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A Pharmacogenomics‐Driven Machine Learning Approach

Author

Myasoedova, Elena, Athreya, Arjun P., Crowson, Cynthia S., Davis, John M., III, Warrington, Kenneth J., Walchak, Robert C., Carlson, Erin, Kalari, Krishna R., Bongartz, Tim, Tak, Paul P., van Vollenhoven, Ronald F., Padyukov, Leonid, Emery, Paul, Morgan, Ann, Wang, Liewei, Weinshilboum, Richard M., and Matteson, Eric L.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results